User login
Key clinical point: Patients with multiple sclerosis (MS) are at an increased risk of cardiovascular and cerebrovascular diseases that traditional risk factors do not fully explain.
Major finding: Compared with people without MS, patients with MS had increased risks for coronary syndrome (hazard ratio [HR], 1.28), cerebrovascular disease (HR, 1.59), any macrovascular disease (HR, 1.32), all-cause mortality (HR, 3.46), and cardiovascular disease mortality (HR, 1.47).
Study details: This population-based, retrospective matched cohort study conducted in England included 12,251 patients with MS and 72,572 people without MS.
Disclosures: The presenting author had no disclosures. Two coauthors received research funding/support from various organizations.
Citation: Palladino R et al. JAMA Neurol. 2020 May 04. doi: 10.1001/jamaneurol.2020.0664.
Key clinical point: Patients with multiple sclerosis (MS) are at an increased risk of cardiovascular and cerebrovascular diseases that traditional risk factors do not fully explain.
Major finding: Compared with people without MS, patients with MS had increased risks for coronary syndrome (hazard ratio [HR], 1.28), cerebrovascular disease (HR, 1.59), any macrovascular disease (HR, 1.32), all-cause mortality (HR, 3.46), and cardiovascular disease mortality (HR, 1.47).
Study details: This population-based, retrospective matched cohort study conducted in England included 12,251 patients with MS and 72,572 people without MS.
Disclosures: The presenting author had no disclosures. Two coauthors received research funding/support from various organizations.
Citation: Palladino R et al. JAMA Neurol. 2020 May 04. doi: 10.1001/jamaneurol.2020.0664.
Key clinical point: Patients with multiple sclerosis (MS) are at an increased risk of cardiovascular and cerebrovascular diseases that traditional risk factors do not fully explain.
Major finding: Compared with people without MS, patients with MS had increased risks for coronary syndrome (hazard ratio [HR], 1.28), cerebrovascular disease (HR, 1.59), any macrovascular disease (HR, 1.32), all-cause mortality (HR, 3.46), and cardiovascular disease mortality (HR, 1.47).
Study details: This population-based, retrospective matched cohort study conducted in England included 12,251 patients with MS and 72,572 people without MS.
Disclosures: The presenting author had no disclosures. Two coauthors received research funding/support from various organizations.
Citation: Palladino R et al. JAMA Neurol. 2020 May 04. doi: 10.1001/jamaneurol.2020.0664.